PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 138 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $44,019 | -39.6% | 2,639 | 0.0% | 0.00% | -100.0% |
Q2 2023 | $72,889 | +154983.0% | 2,639 | +28.8% | 0.00% | – |
Q1 2023 | $47 | +113.6% | 2,049 | 0.0% | 0.00% | – |
Q4 2022 | $22 | -99.9% | 2,049 | +2.4% | 0.00% | – |
Q3 2022 | $16,000 | 0.0% | 2,000 | 0.0% | 0.00% | – |
Q2 2022 | $16,000 | -97.4% | 2,000 | -92.4% | 0.00% | -100.0% |
Q1 2022 | $625,000 | -21.4% | 26,390 | -2.8% | 0.00% | -33.3% |
Q4 2021 | $795,000 | +9837.5% | 27,150 | +5933.3% | 0.01% | – |
Q3 2021 | $8,000 | -60.0% | 450 | 0.0% | 0.00% | – |
Q2 2021 | $20,000 | +66.7% | 450 | 0.0% | 0.00% | – |
Q1 2021 | $12,000 | +33.3% | 450 | 0.0% | 0.00% | – |
Q4 2020 | $9,000 | – | 450 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |